Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase I/II study of ABSK061 in children with achondroplasia
CTR20252422Phase 2Active
- Sponsor
- Abbisko Therapeutics
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lavengratinib in achondroplasia (ACH), sponsored by Abbisko Therapeutics. Started Dec 2025; status: active.
02
Drugs
lavengratinib
03
Conditions
achondroplasia (ACH)
Beyond the preview
Go deeper on CTR20252422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252422.